ORIGINAL ARTICLE. Dolvy Girawan*, SA Abdurachman*, Ali Djumhana*, Juke Roslia S*, Riardi Pramudiyo**
|
|
- Gavin Simpson
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Comparison of Endoscopic Gastric Mucosa Features After Administration of Piroxicam to Meloxicam and Their Correlation with Symptoms in Elderly Patient with Knee Osteoarthritis Dolvy Girawan*, SA Abdurachman*, Ali Djumhana*, Juke Roslia S*, Riardi Pramudiyo** ABSTRACT Aim: to know the effect of piroxicam (COX-1 and COX-2 inhibitor NSAID) and meloxicam (selective COX-2 inhibitor NSAID) against the gastric mucosa. Methods: a random, double-blind-parallel study and repeat measurement against 20 elderly-patients with knee-oa was conducted. Patients were divided into 2 equal groups, every group got piroxicam 20 mg/day or meloxicam 15 mg/day for 3 weeks. On the second group, sukralfat 2 x 1 g/day were given. To examine the difference before and after treatment, we used Wilcoxon signed rank test, to examine the difference within those groups we used Mann-whitney U test, to examine the correlation between endoscopic score and dyspepsia, we used the Spearman correlation test with significant correlation interpretation by Guilford rules. Results: one of piroxicam group was resigned, so that there was 19 person left to complete this study. Piroxicam has caused elevation of endoscopic score in 78% subject compared to the beginning of study, and 22% of the subject has developed ulcers. Alteration of endoscopic feature after administration of this piroxicam was statistically significant (p < 0,05). Mild dyspepsia symptoms after piroxicam administration were positive on 67% subjects (p < 0,05). After administration of meloxicam, 40% subjects have elevated endoscopic score compared to beginning of the study (p < 0,05). Mild dyspepsia symptoms after meloxicam administration were positive on 40% subjects (p > 0,05). Meloxicam has less elevation of endoscopic score compared to the piroxicam (p < 0,05). By statistics, both of groups showed no difference in dyspepsia symptoms (p > 0,05). There was no significant correlation between elevation of endoscopic score and dyspepsia on both of groups. Nevertheless, it tends to have weak positive correlation * Division of Gastroenterohepatology, ** Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Padjajaran / Hasan Sadikin Hospital, Bandung (piroxicam group r = 0,306; p > 0,05, meloxicam group r = 0,330; p > 0,05). Conclusion: on this study, we conclude that the administration of either piroxicam or meloxicam in elderly-patient with knee-oa has caused the gastric mucosa impairment. The impairment after meloxicam administration is milder than piroxicam. There is no significant difference of dyspepsia symptoms in both of groups. There is no correlation between endoscopic gastric mucosa features with the dyspepsia symptoms. Key words: piroxicam, meloxicam, endoscopic score, dyspepsia INTRODUCTION The growing life expectancy has caused larger amount of elderly citizen. 1 Osteoarthritis is chronic disease that often predominantly found in elderly. 2 In general, Osteoarthritis patients usually have tried to overcome their disease themselves and have tried various manner to reduce or to eliminate their pain symptoms such as by o.t.c. drugs that have been promoted to reduce the pain. 3 Since 1970, non-seroid anti inflammatory drugs has been widely used over the world. 4 In outpatient rheumatology clinic of Hasan Sadikin Hospital, Bandung, in the period of July 1999 to June 2000, Osteoarthritis had the first rank (68.61%) and most of them were about knee (86.75%). 5 The drug that most widely used to overcome pain in Osteoarthritis is NSAID. Besides of its analgesic and anti-inflammatory effect, NSAID also has side effect on gastrointestinal system. The therapeutic and side effects are caused by inhibition on cyclooxygenase (COX) enzyme, which play role to convert the arachidonate acid into prostaglandin
2 Vol 36 Number 4 October-December 2004 Comparison of Endoscopic Gastric Mucos Features There are 2 COX iso-enzyme, i.e. the constitutive COX-1, which has role in physiological fuction and the inducible COX-2, which has role in inflammation reaction. 7 In pharmacology, NSAID has developed from unselective drugs to selective drugs against COX-2. 8 The old generation of NSAID (indomethacine, piroxicam, ibuprofen, aspirin, etc) inhibit both COX-2 and COX-1, so that in therapeutic dose it may cause side effect, predominantly on gastrointestinal tract. 9,10 The new NSAID selectively inhibit COX-2, thus theoretically it has less side effect on gastrointestinal tract. 9,10 Considering the low gastrointestinal side effect on the patient who had COX-2 selective inhibitor NSAID, then this study was conducted, by comparing how much the alteration of gastric mucosa with the usage of COX- 2 selective inhibitor NSAID compared to the NSAID that inhibits COX-1 and COX-2. In this study, by ethical consideration in order to reduce the side effect of NSAID on the stomach, we used sukralfat 2 x 1 g/day. METHODS This study is a double blind clinical trial, with parallel design enclosed by repeated measurement. The study was conducted at. Dr. Hasan Sadikin Hospital, Bandung, since March 2002 August The subject was part of the study of The Effect of Meloxicam and Piroxicam Against Renal Hemodynamic on elderly patient with knee osteoarthritis. 11 Through the random permuted blocks, 12 patients were allocated to have meloxicam 1 x 15 mg/day or piroxicam 1 x 20 mg/day for 3 weeks period. The inclusion criteria for this study were all outpatient subject with symptomatic knee osteoarthritis and had not had any NSAID minimal in the period of three weeks before the study began, signing the informed consent, first endoscopic examination was normal, or if the mucosa was abnormal, then they had maximal defect as followed: hyperemia or erosion with endoscopic score 3 (in keeping with endoscopic score table by Lanza). 13 The exclusion criteria were: if the patient had any allergy of NSAID, blood pressure over 140/90 mmhg or hypertension patient which has undergone treatment, renal function disorder (serum creatinine >2,0 mg/dl), had used any diuretics, anticoagulants, metotrexate, misoprostol, or steroid, had any dyspepsia symptoms in last 2 weeks, had any history of gastric ulcer or gastrointestinal bleeding resulted by ulcer or NSAID, suffered for liver disease, liver cirrhosis, or the value of transaminase enzyme was³ 2 times of highest normal value, the thrombocyte was < /mm 3 ), positive history of congestive heart failure. The sample size was determined by nonstatistical measures, because of cost consideration, then it was conducted for 20 elderly patient with knee osteoarhritis. The endoscopic diagnosis was established based on the table 1. Table 1. The 13 Endoscopic Score Description 0 Normal Mucosa Petechiae 2 > 10 Petechiae Erosion Erosion Erosion 6 > 25 Erosion 7 Ulcer Classification criteria for knee osteoarthritis 14 knee pain plus minimal one of 3 conditions as follow: Age > 50 years Stiffness < 30 minute Crepitation (+) Positive osteophyte by radiology The dyspepsia symptoms categorized by Talley 15 into mild, normal and severe dyspepsia. To examine the difference before and after treatment by ordinal rate measurement, we used Wilcoxon Signed-rank test, to examine the difference between the group that had piroxicam and had meloxicam, we used Mann-whitney U test. 16 To know relationship between endoscopic score and dyspepsia, we used Spearman correlation test, with significant correlation interpretation by Guilford rules. 17 RESULTS By randomized and double blind methods, the subjects were divided into 2 groups i.e. 10 person in A group and 10 person in B group. One of male in A group was resigned. The Patient s General Characteristic The comparison of general characteristic of subjects, i.e. the A and B group could be seen on table 2. Male patients were lesser than the females i.e. 6 males (30%) and 14 females (70%). We could see that the patient s general characteristic on both of group has no significant difference. 203
3 Dolvy Girawan, etal Acta Med Indones-Indones J Intern Med Table 2. General Characteristic of Patient at Beginning of Study CHARACTERISTIC GROUP A (n=9) GROUP B (n=10) Z p X SD X SD - Age (years) Hb (g/dl) Leukocyte (10 2 /mm 3 ) Thrombocyte (10 3 mm 3 ) SGOT (U/I) SGPT (U/l) Ureum (mg/dl) , creatinine (mg/dl) The Result of Endoscopic Examination and Before Having Treatment On table 3 we could see the result of endoscopic examination before having treatment. The difference of endoscopic score within those group before having treatment were not significant (p > 0,05). The dyspepsia score on group A and B were 0 (normal) because if there was any dyspepsia symptom then they could not participate in this study. Table 3. The Result of Endoscopic Examination Before Having Treatment Group A Group B Score n (%) Score n (%) 0 1 (11) 0 1 (10) 1 2 (22) 1 1 (10) 2 2 (22) 2 1 (10) 3 4 (45) 3 7 (70%) Total 9 (100) 10 (100) The Effect of Piroxicam Against Gastric Mucous Based on this study, piroxicam administration had increased the endoscopic score. In this study, 78% of them had worse gastric mucosa impairment compared to before having treatment. About 22% had developed ulcer on antrum pyloric (Table 4). This alteration was statistically significant (p < 0,05). All of the patient on piroxicam group had more severe impairment of gastric mucosa compared to before treatment (Figure 1). The Effect of Meloxicam Against Gastric Mucosa On table 4, we could see that after having meloxicam, 40% of them had more severe impairment of gastric mucosa. The alteration of this endoscopic score was statistically significant (p < 0,05). The endoscopic score of four patients (40%) were unaltered. (Figure 2) Figure 1. The Before and After Having Piroxicam Subject Subject Figure 2. The Before and After Having Meloxicam Comparison of The Altered Within The Groups The alteration of endoscopic score after meloxicam administration was lesser than piroxicam. The comparison of endoscopic score on both groups were significantly different (p < 0,05). The Effect Piroxicam And Meloxicam Effect Against Symptom On table 5 we could see that piroxicam had increased the dyspepsia symptoms. About 67% had mild dyspepsia (p < 0,05). On the meloxicam group, about 40% had mild dyspepsia, but this alteration was not significant (p > 0,05). The alteration of dyspepsia score on both of groups had no significant difference (p > 0,05). Pre Post Pre Post 204
4 Vol 36 Number 4 October-December 2004 Comparison of Endoscopic Gastric Mucos Features Table 4. The Result of Endoscopic Examination Before and After Having Treatment Piroxicam Meloxicam Score Before After Score Before After 0 1 (11) (10) (22) (10) (22) (10) 1 (10) 3 4 (45) 2 (22) 3 7 (70) 5 (50) (11) (40) (11) (34) (22) Total 9 (100) 9 (100) 10 (100) 10 (100) Table 5. Symptoms Before and After Treatment Piroxicam Meloxicam Before After Before After Normal 9 (100) 3 (33) Normal 10 (100) 6 (60) Mild 0 6 (67) Mild 0 4 (40) Normal 0 0 Normal 0 0 Severe 0 0 Severe 0 0 Total 9 (100) 9 (100) 10 (100) 10 (100) Correlation Between and on Piroxicam Treatment From figure 3, we could see that there was no significant difference about endoscopic score and dyspepsia (p > 0,05). Nevertheless, it tend to have weak positive correlation. severe moderate mild severe moderate r = p = Figure 4. The Correlation Between and Symptoms After Meloxicam Administration mild Figure 3. The Correlation Between and After Piroxicam Treatment Correlation Between The and on Meloxicam Treatment On figure 4, we could see that the correlation between endoscopic score and dyspepsia after meloxicam administration was not significant (p > 0.05). After having meloxicam, eventhough it was not significant, it appeared to have weak positive correalation between the endoscopic score and dyspepsia (r = 0.330). DISCUSSION The mean age of subjects was over 60 years old. It was the high-risk group of gastric mucosa impairment resulted from NSAID. Before treatment, most of the patient had already had gastric mucosa impairment. In this study, we could see that either piroxicam or meloxicam had caused the gastric mucosa impairment. The piroxicam administration had cause more severe impairment compared to the meloxicam. The study of Patoia et al 18 demonstrated that meloxicam had not caused significant increase of endoscopic score. On this study, the meloxicam administration had increased the endoscopic score significantly compare to endoscopic score before 205
5 Dolvy Girawan, etal Acta Med Indones-Indones J Intern Med having treatment. The different result of this study and the Patoia et al study may caused by smaller n amount and difference of subject selection. By ethical consideration, we gave sukralfat in this study in order to protect the gastric mucosa. But, in reality, the gastric mucosa impairment after piroxicam or meloxicam administration had happened. This indicated that sukralfat as one of cytoprotector drugs was not fully prevent the gastric mucosa impairment by NSAID. There was mild dyspepsia symptom on most of patient after piroxicam administration. On the meloxicam group, after drug treatment, there was no significant alteration about the dyspepsia symptoms. Comparison of dyspepsia symptoms after drug administration on both of groups had no significant difference. In this study, even there was no correlation between endoscopic features and dyspepsia but it appeared to have tendencies of weak positive correlation either on piroxicam or meloxicam group. This result was different in Larkai et al 19 and Wallace 20 study, which explained that there was no correlation between endoscopic defect and the dyspepsia symptoms, so we need more clarification through studies with more optimal and larger sample. CONCLUSION The administration of 20 mg/day piroxicam or meloxicam 15 mg/day for 3 weeks on the elderly patient with knee osteoarthritis may cause gastric mucosa impairment. Meloxicam has milder effect of gastric mucosa impairment compared to the piroxicam There was no difference of dyspepsia symptoms after administration of piroxicam or meloxicam. There was no correlation between the gastric mucosa impairment by endoscopic with the dyspepsia symptoms after administration of piroxicam or meloxicam. REFERENCES 1. Boedi D. Masalah lanjut usia di Indonesia. Makalah pada kongres I Asosiasi Alzheimer Indonesia tahun Whelton A, Fort JG, Puma JA. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8: Brooks P. Use and benefits of non steroidal anti-inflammatory drugs. Am J Med 1998;104 (3A):9S-13S. 4. Bloom BS. Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989;149: Jamil KF, Pramudiyo R, Wachyudi RG. Pola penyakit reumatik pada penderita rawat jalan dan rawat inap di sub bagian Reumatologi, Bag/SMF Ilmu Penyakit Dalam FKUP/RSUP Dr. Hasan Sadikin Bandung selama periode bulan Juli 1999 sampai Juni Diajukan pada kongres Reumatologi nasional tahun Bjorkman DJ. The effect of aspirin and non steroidal antiinflammatory drugs on prostaglandins. Am J Med 1998;105(1B):8S-12S. 7. Vane SJ. Aspirin and other anti-inflamatory drugs. Thorax 2000;55(suppl 2):S3-S9. 8. Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman, Sleisenger & Fordtran s, eds. Gastrointestinal and liver disease. 6 th ed. Philadelphia:W.B. Saunders Co.;1998. p Wallace JL. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles and the categorization of nonsteroidal anti-inflammatory drugs (NSAID). Am J Med 1999;107 (6A):11S-7S. 10. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104: Chandra S. Efek meloxicam dan piroxicam terhadap hemodinamik ginjal pada penderita osteoartritis genu usia lanjut. Tesis Spesialis-1 Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Padjadjaran Bandung Pocock SJ. Clinical trials: a practical approach. New York: John Wiley & Son, Lanza FL, Kochman RL, Geis GS, Rack RN, Deysach LG. A double-blind, placebo-controlled trial, 6-days evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowell habits. Am J Gastroenterol 1991;86: Altman R, Asch E, Bloch G. Development of criteria for the clasification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29: Talley NJ, Mc Neil D, Peper DW. Discriminant value of dyspeptic symptoms; a study of the clinical presentation of 221 patients with dyspepsia of unknown cause, peptic ulceration and cholelithiasis. Gut 1987;28: Dawson SB, Trapp RG. Basic and clinical biostatistics. 2 nd ed. USA: Appleton and Lange; Guilford JP. Fundamental statistics in psychology and education. New York: McGraw-Hill; Patoia L, Santucci L, Furno L. A 4-week double-blind parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996; 35(Suppl 1): Larkai EN, Smith JL, Lidsky MD,Graham DY. Gastroduodenal mucosa and dyspeptic symtoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;8(22): Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997;112:
Gastrointestinal Safety of Coxibs and Outcomes Studies: What s the Verdict?
Vol. 23 No. 4S April 2002 Journal of Pain and Symptom Management S5 Proceedings from the Symposium The Evolution of Anti-Inflammatory Treatments in Arthritis: Current and Future Perspectives Gastrointestinal
More informationDouble-blind comparison of efficacy and
Annals of the Rheumatic Diseases 1993; 52: 881-885 881 Searle, Box 5110, Chicago, Ill 60680-5110, USA J A Melo Gomes S H Roth J Zeeh G A W Bruyn E M Woods G S Geis Correspondence to: Dr G S Geis Accepted
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationMitigating GI Risks Associated with the Use of NSAIDs
bs_bs_banner Pain Medicine 2013; 14: S18 S22 Wiley Periodicals, Inc. Mitigating GI Risks Associated with the Use of NSAIDs Mahnaz Momeni, MD,* and James D. Katz, MD Departments of *Rheumatology, Medicine,
More informationNSAIDs: Side Effects and Guidelines
NSAIDs: Side Effects and James J Hale FY1 Department of Anaesthetics Introduction The non-steroidal anti-inflammatory drugs (NSAIDs) are a diverse group of drugs that have analgesic, antipyretic and anti-inflammatory
More informationMonth/Year of Review: January 2012 Date of Last Review: February 2007
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Month/Year of Review: January 2012 Date of Last Review:
More informationReview Article. Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) Safety Profile of NSAID
Safety Profile of Nonsteroidal Antiflammatory Drugs (NSAID) R. Stoilov: University Hospital St Ivan Rilski, Clinic of Rheumatology Contact: Rumen Stoilov, Clinic of Rheumatology, University Hospital St
More informationMeta-analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials
Alimentary Pharmacology & Therapeutics Meta-analysis: incidence of endoscopic gastric and duodenal ulcers in placebo arms of randomized placebo-controlled NSAID trials Y.-H. YUAN*,, C. WANG*, Y. YUAN*
More informationNonsteroidal anti-inflammatory drugs (NSAIDs),
GASTROENTEROLOGY 2001;120:594 606 Approaches to Nonsteroidal Anti-inflammatory Drug Use in the High-Risk Patient LOREN LAINE University of Southern California School of Medicine, Los Angeles, California
More informationSummary. Introduction
Osteoarthritis and Cartilage (2002) 10, 290 296 2002 Published by Elsevier Science Ltd on behalf of OsteoArthritis Research Society International 1063 4584/01/040290+07 $22.00/0 doi:10.1053/joca.2001.0510,
More informationOriginal Article. Abstract. Introduction
Original Article Frequency of NSAID Induced Peptic Ulcer Disease Saeed Hamid, Javed Yakoob, Wasim Jafri, Shanul Islam, Shahab Abid, Muhammad Islam Section of Gastroenterology, Department of Medicine, Aga
More informationORIGINAL ARTICLE. Abstract
ORIGINAL ARTICLE Prescription of Nonsteroidal Anti-inflammatory Drugs and Co-prescribed Drugs for Mucosal Protection: Analysis of the Present Status Based on Questionnaires Obtained from Orthopedists in
More informationThe cardioprotective benefits of ... REPORTS... Gastrointestinal Safety of Low-Dose Aspirin. Byron Cryer, MD
... REPORTS... Gastrointestinal Safety of Low-Dose Aspirin Byron Cryer, MD Abstract The cardioprotective benefits of aspirin support the use of low-dose regimens for primary and secondary prevention of
More informationDrug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Preliminary Scan Report #2 May 2014 Last Report: Update #4 (November 2010) Last Preliminary Scan: July 2013 The purpose of reports is to make
More informationPrevalence of gastroduodenal lesions in chronic nonsteroidal anti-inflammatory drug users presenting with dyspepsia at the Kenyatta National Hospital
Research Article Department of Clinical Medicine and Therapeutics, University of Nairobi, Kenya Corresponding author: Dr. G O Oyoo. Email: geomondi@hotmail. com Prevalence of gastroduodenal lesions in
More informationD DAVID PUBLISHING. 1. Introduction. Maher Mbarki 1, Helen Sklyarova 1, Krystyna Aksentiychuk 1, Ihor Tumak 2 and Eugene Sklyarov 1
Journal of Pharmacy and Pharmacology (2016) 32-36 doi: 10.17265/232-2150/2016.0.011 D DAVID PUBLISHING Plasma Levels of Leukotriene B and Prostaglandin E2 Correlation with Endoscopic Changes after NSAID
More informationEffective management of gastrointestinal PROCEEDINGS EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS *
EVALUATING THE APPROACHES TO SAFE AND EFFECTIVE ANALGESIA FOR OLDER PATIENTS WITH ARTHRITIS * David A. Peura, MD, FACP, FACG ABSTRACT *This article is based on a presentation given by Dr Peura at the PRI-MED
More informationNSAIDs Overview. Souraya Domiati, Pharm D, MS
NSAIDs Overview Souraya Domiati, Pharm D, MS Case A 32 years old shows up into your pharmacy asking for an NSAID for his ankle pain He smokes1 pack/day His BP is 125/75mmHg His BMI is 35kg/m2 His is on
More informationThis document has not been circulated to either the industry or Consultants within the Suffolk system.
New Medicine Report Document Status COX II Inhibitors In Acute Analgesia For Suffolk Drug & Therapeutics Committee Date of Last Revision 15 th February 2002 Reviewer s Comments There seems to be a growing
More informationDrug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report
More informationOSTEOARTHRITIS; EFFICACY AND SAFETY OF ACECLOFENAC IN THE TREATMENT: A RANDOMIZED DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL VERSUS DICLOFENAC
The Professional Medical Journal www.theprofesional.com ORIGINAL PROF-416 OSTEOARTHRITIS; EFFICACY AND SAFETY OF ACECLOFENAC IN THE TREATMENT: A RANDOMIZED DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL VERSUS
More informationNONSTEROIDAL ANTI- INFLAMMATORY DRUGS
NONSTEROIDAL ANTI- INFLAMMATORY DRUGS MRS. M.M. HAS A 3 YR. HX OF PROGRESSIVE RIGHT HIP PAIN. THE PAIN INCREASES WITH WEIGHT BEARING ACTIVITY. PT. HAS BEEN ON ACETAMINOPHEN WITHOUT RELIEF. PERTINENT LABS
More informationNon-steroidal anti-inflammatory drugs and gastrointestinal damage problems and solutions
82 University of Glasgow and Department of Gastroenterology, Royal Infirmary, Glasgow Correspondence to: Professor R I Russell, 28 Ralston Road, Bearsden, Glasgow G61 3BA rirla@aol.com Submitted 26 October
More informationReview Article. NSAID Gastropathy: An Update on Prevention. Introduction. Risk Factors. Kam-Chuen Lai
Review Article NSAID Gastropathy: An Update on Prevention Kam-Chuen Lai Abstract: Keywords: Adverse reactions to non-steroidal anti-inflammatory drugs (NSAIDs) are common. Upper gastrointestinal complications
More informationPrevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best?
Prevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best? Shaden Salamae MD a, Meir Antopolsky MD a, Ruth Stalnikowicz MD a * Department of Emergency Medicine, Hadassah University
More information4.0 STUDY DESCRIPTION
4.0 STUDY DESCRIPTION 4.1 Subject Selection A sufficient number of subjects will be enrolled to ensure that a total of 800 evaluable subjects complete the study. 4.1.1 Inclusion Criteria 1. The patient
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationSPECIAL REPORT. Aspirin and Risk of Gastroduodenal Complications
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:725 735 SPECIAL REPORT Proton Pump Inhibitors for Gastroduodenal Damage Related to Nonsteroidal Anti-inflammatory Drugs or Aspirin: Twelve Important Questions
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationComplementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib
Aliment Pharmacol Ther 2003; 17: 201 210. doi: 10.1046/j.0269-2813.2003.01407.x Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib R. H. HUNT*,
More informationMUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed
MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and
More informationGastrointestinal Tolerability of Ibuprofen Compared with Paracetamol and Aspirin at Over-the-counter Doses
The Journal of International Medical Research 2002; 30: 301 308 Gastrointestinal Tolerability of Ibuprofen Compared with Paracetamol and Aspirin at Over-the-counter Doses P RAMPAL 1, N MOORE 2, E VAN GANSE
More informationA HISTOLOGICAL STUDY OF THE EFFECTS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) ON THE GASTRIC AND DUODENAL MUCOSA
A HISTOLOGICAL STUDY OF THE EFFECTS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) ON THE GASTRIC AND DUODENAL MUCOSA Abstract Pages with reference to book, From 287 To 290 Naheed Moghal, N.A. Jafarey
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Celebrex) Reference Number: CP.PMN.122 Effective Date: 01.01.07 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationPapers. Abstract. Introduction. Methods. Jonathan J Deeks, Lesley A Smith, Matthew D Bradley
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials Jonathan J Deeks, Lesley
More informationCorrelation between Postural Stability and Functional Mobility in Patients with Knee Osteoarthritis
550 AMJ December, 2015 Correlation between Postural Stability and Functional Mobility in Arlinda De Hafsari, 1 Vitriana, 2 Alwin Tahid 3 1 Faculty of Medicine, Universitas Padjadjaran, 2 Departmen of Physiology
More informationPain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia
Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans. 1 Pain
More informationIroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low
More informationPain therapeutics. Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain
Pain therapeutics Acetaminophen/NSAIDs Acute pain Osteoarthritis Migraine Acute Gout Neuropathic pain James McCormack, Pharm.D. Professor Faculty of Pharmaceutical Sciences, UBC Common types of pain killers
More informationPain: A Public Health Challenge. NSAIDS for Managing Pain. Iroko: Innovators in Analgesia
Pain: A Public Health Challenge Despite advances in understanding and treatment, pain remains a major public health challenge 1 that exacts a significant personal and economic toll on Americans 2. Pain
More informationEffective Health Care Program
Comparative Effectiveness Review Number 38 Effective Health Care Program Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review Executive Summary Background Osteoarthritis
More information4 2 Osteoarthritis 1
Osteoarthritis 1 Osteoarthritis ( OA) Osteoarthritis is a chronic disease and the most common of all rheumatological disorders. It particularly affects individuals over the age of 65 years. The prevalence
More informationRimoxen. Rimoxen! "The Gastro and Cardio friendly anti-inflammatory ingredient"
Rimoxen A Botanical Anti-Inflammatory COX-2 Selective Ingredient Question: How doses Rimoxen compare to the prescription COX-2 inhibitors (Vioxx and Celebrex) and the OTC NSAID pain relievers such as aspirin
More informationCelecoxib: the need to know for safe prescribing
medicine indications pain management rheumatology Celecoxib: the need to know for safe prescribing Celecoxib is a selective cyclo-oxygenase-2 (COX-2) inhibitor that has been fully subsidised without restriction,
More informationHave COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?
et al. DOI:10.1111/j.1365-2125.2003.02012.x British Journal of Clinical Pharmacology Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs? Mary Teeling, Kathleen Bennett
More informationNon-steroidal anti-inflammatory drugs: who should receive prophylaxis?
Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 59 64. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? C. J. HAWKEY Wolfson Digestive Diseases Centre, Institute of Clinical Research,
More informationWhich peptic ulcer patients bleed?
Gut, 1988, 29, 70-74 Which peptic ulcer patients bleed? K MATTHEWSON, S PUGH, AND T C NORTHFIELD From the Gastroenterology Units, St James Hospital, Balham and University College Hospital, London SUMMARY
More informationIn 1971, Sir John Vane proposed that nonsteroidal
Non-steroidal antiinflammatory drugs: facts and fallacies This article serves to review NSAIDs, their mechanism of action and adverse effects, as well as to establish the therapeutic position of the new-generation
More informationDyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac
Aliment Pharmacol Ther 2002; 16: 819 827. Dyspepsia tolerability from the patients perspective: a comparison of celecoxib with diclofenac J. L. GOLDSTEIN*, G. M. EISEN, T. A. BURKEà, B. M. PEÑA, J. LEFKOWITH
More informationNSAID-Induced Gastrointestinal Damage
GASTROENTEROLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician Gastroenterology Board Review Manual is a study guide for fellows and practicing physicians preparing for board
More informationPhospholipid Association Reduces the Gastric Mucosal Toxicity of Aspirin in Human Subjects
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 94, No. 7, 1999 1999 by Am. Coll. of Gastroenterology ISSN 0002-9270/99/$20.00 Published by Elsevier Science Inc. PII S0002-9270(99)00267-1 Phospholipid Association
More informationRisk Management Plan Etoricoxib film-coated tablets
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis (OA): OA is a condition in which the cartilage of the joints is broken down. This causes stiffness, pain and leads
More informationETIOPATHOGENICAL ASPECTS OF NONSTEROIDAL ANTI- INFLAMMATORY DRUGS IN ELDERLY Mihaela Bursova¹, Gabriela Lilios², Maria Suta³, Gh.
ETIOPATHOGENICAL ASPECTS OF NONSTEROIDAL ANTI- INFLAMMATORY DRUGS IN ELDERLY Mihaela Bursova¹, Gabriela Lilios², Maria Suta³, Gh. Taralunga² 1.CLINICAL EMERGENCY COUNTY HOSPITAL CONSTANŢA, GERIATRICS DEPARTAMENT
More informationIs ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use?
ORIGINAL PAPER doi: 10.1111/j.1742-1241.2006.01147.x Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? N. D. YEOMANS, 1 *L-ESVEDBERG,
More informationEffect of Breadfruit Leaves Infusion on Acute Renal Failure Rat Model
511 Effect of Breadfruit Leaves Infusion on Acute Renal Failure Rat Model Muhamad Risdan Hardani 1, Herri S. Sastramihardja 2, Afiatin 3 1 Faculty of Medicine Universitas Padjadjaran, 2 Department of Pharmacology
More informationA study on clinical profile and risk factors in drug induced UGI bleeding
Original Research Article A study on clinical profile and risk factors in drug induced UGI bleeding S. Appandraj 1*, V. Sakthivadivel 2 1,2 Associate Professor, Dept. of General Medicine, Karpaga Vinayaga
More informationEvidence-based medicine: data mining and pharmacoepidemiology research
Data Mining VII: Data, Text and Web Mining and their Business Applications 307 Evidence-based medicine: data mining and pharmacoepidemiology research B. B. Little 1,2,3, R. A. Weideman 3, K. C. Kelly 3
More informationSystematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs
Alimentary Pharmacology & Therapeutics Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs L. LAINE*, R. SMITH, K.MIN, C.CHENà &R.W.DUBOIS *Division of
More informationAcetaminophen and NSAIDS. James Moriarity MD University of Notre Dame
Acetaminophen and NSAIDS James Moriarity MD University of Notre Dame Lecture Goals Understand the indications for acetaminophen and NSAID use in musculoskeletal medicine Understand the role of Eicosanoids
More informationAlgorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs)
Algorithm for Use of Non-steroidal Anti-inflammatories (NSAIDs) Page 3 Publisher Conseil du médicament www.cdm.gouv.qc.ca Coordination Anne Fortin, Pharmacist Development Conseil du médicament Fédération
More informationA Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury
A Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury A. Mark Fendrick, MD Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed often in the U.S., particularly
More informationPHARMACOTHERAPEUTIC ANALYSIS OF NON- STEROIDAL ANTI-INFLAMMATORY DRUGS PRESCRIBED AT RHEUMATOLOGY / ORTHOPEDIC CLINICS. Waleed M.
J. Al Azhar University-Gaza 2003,Vol. 6, 2 P.47-56 PHARMACOTHERAPEUTIC ANALYSIS OF NON- STEROIDAL ANTI-INFLAMMATORY DRUGS PRESCRIBED AT RHEUMATOLOGY / ORTHOPEDIC CLINICS. Waleed M. Sweileh An-Najah National
More informationAspirin is used widely as an antithrombotic drug for
GASTROENTEROLOGY 2004;127:395 402 Ulcer Formation With Low-Dose Enteric-Coated and the Effect of COX-2 Selective Inhibition: A Double-Blind Trial LOREN LAINE,* ERIC S. MALLER, CHANG YU, HUI QUAN, and THOMAS
More informationRole of Helicobacter pylori in ulcer healing and
22 Departments of Gastroenterology G Bianchi Porro F Parente V Imbesi and Rheumatology F Montrone I Caruso L Sacco University Hospital, Milan, Italy Correspondence to: Professor G Bianchi Porro, Gastrointestinal
More informationProtection of human gastric mucosa against aspirinðenteric coating or dose reduction?
Aliment Pharmacol Ther 1999; 13: 187±193. Protection of human gastric mucosa against aspirinðenteric coating or dose reduction? A. T. COLE*, N. HUDSON*, L. C. W. LIEW*, F. E. MURRAY*, C. J. HAWKEY* & S.
More informationHip, n (%) Left Right Left Right Left Right Left Right Left Right 81 (21.2) 87 (22.8) 79 (20.7)
FLEXISEQ : An innovative treatment for the management of pain and stiffness in patients with osteoarthritis: Real-life data from a patient survey of members of the Feierabend Community Abstract FLEXISEQ
More informationThe effects of acetylsalicylic acid on swelling, pain and other
Br. J. clin. Pharmac. (1984), 17, 379-384 The effects of acetylsalicylic acid on swelling, pain and other events after surgery P. SKJELBRED Institute of Pharmacology, and Department of Oral Surgery and
More informationEvidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1156 1163 REVIEW Evidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm ANDREW MOORE,* INGVAR
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: , VERSION 1
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: 15-5-2015, VERSION 1 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Musculoskeletal pain: Musculoskeletal
More informationEfficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs
Alimentary Pharmacology & Therapeutics Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs C. J. HAWKEY*,
More information-Mohammad Ashraf. -Anas Raed. -Alia Shatnawi. 1 P a g e
-1 -Mohammad Ashraf -Anas Raed -Alia Shatnawi 1 P a g e Dr. Alia started the lecture by talking about subjects we are going to cover through this course; you can refer to the record if you are interested.
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationThe New England Journal of Medicine
VERSUS AND IN REDUCING THE RISK OF RECURRENT ULCER BLEEDING IN PATIENTS WITH ARTHRITIS FRANCIS K.L. CHAN, M.D., LAWRENCE C.T. HUNG, M.D., BING Y. SUEN, R.N., JUSTIN C.Y. WU, M.D., KENNETH C. LEE, PH.D.,
More informationCHOLINE MAGNESIUM TRISALICYLATE VS NAPROXEN IN THE SYMPTOMATIC TREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMIZED CLINICAL TRIAL
Academic Sciences Asian Journal of Pharmaceutical and Clinical Research Vol 5, Issue 1, 212 ISSN - 974-2441 Research Article CHOLINE MAGNESIUM TRISALICYLATE VS NAPROXEN IN THE SYMPTOMATIC TREATMENT OF
More informationUpper Gastrointestinal Bleeding Score for Differentiating Variceal and Nonvariceal Upper Gastrointestinal Bleeding ABSTRACT
44 Original Article Upper Gastrointestinal Bleeding Score for Differentiating Variceal and Jaroon Chasawat Varayu Prachayakul Supot Pongprasobchai ABSTRACT Background: Upper gastrointestinal bleeding (UGIB)
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Coxib and traditional NSAID Trialists (CNT)
More informationCOLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet
COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug
More informationCimetidine decreases indomethacin induced duodenal
Gut, 1988, 29, 1578-1582 Cimetidine decreases indomethacin induced duodenal mucosal damage in patients with acute musculoskeletal disorders R STALNIKOWICZ, D POLLAK, A ELIAKIM, D WENGROWER, A FICH, E GOLDIN,
More informationNSAID Regional Audit Group Presentation. Audit Group: Dr Richard Latten, Ruth Clark, Dr Sarah Fradsham, Dr Seamus Coyle, Claire Johnston
NSAID Regional Audit Group Presentation Audit Group: Dr Richard Latten, Ruth Clark, Dr Sarah Fradsham, Dr Seamus Coyle, Claire Johnston Thank you from the audit group for all who participated in the data
More informationToxicities of Drugs Used in the Management of Fever
S219 Toxicities of Drugs Used in the Management of Fever Karen I. Plaisance University of Maryland School of Pharmacy, Baltimore Fever is frequently managed outside the purview of medical professionals,
More informationConclusion: GI symptoms are common among patients with rheumatic disorders. Medications
419 Original Article Higher prevalence of gastrointestinal symptoms among patients with rheumatic disorders Chong V H, Wang C L ABSTRACT Introduction: Chronic disorders, such as rheumatic disorders, are
More informationDouble-blind randomized controlled trial of isoxicam vs piroxicam in elderly patients with osteoarthritis of the hip and knee
Br. J. clin. Pharmac. (1986), 22, 149S-155S Double-blind randomized controlled trial of isoxicam vs piroxicam in elderly patients with osteoarthritis of the hip and knee N. BELLAMY"'2, W. W. BUCHANAN2
More informationV Roy*, U Gupta*, S Sharma**, B K Dhaon***, N P Singh****, P Gulati*****
Comparative Efficacy and Tolerability of Nimesulide and Piroxicam in Osteoarthritis with Specific Reference to Chondroprotection : A Double Blind Randomised Study V Roy*, U Gupta*, S Sharma**, B K Dhaon***,
More informationAN NSAID WITH A BALANCED COX-1 & COX-2 INHIBITORY EFFECT
AN NSAID WITH A BALANCED COX-1 & COX-2 INHIBITORY EFFECT A balanced cox-1 and cox-2 inhibitor Metabolisim and Bioavailabillty of Lornoxicam (3) Relative selectivity of agents as inhibitors of cox-1 and
More informationORIGINAL ARTICLE. Abstract INTRODUCTION
International Journal of Rheumatic Diseases 2018 ORIGINAL ARTICLE Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal
More informationScottish Medicines Consortium
Scottish Medicines Consortium ketoprofen/, 100mg/20mg; 200mg/20mg modified release capsules (Axorid ) No. (606/10) Meda Pharmaceuticals 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationIroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults
Iroko Pharmaceuticals Announces Acceptance for Filing of ZORVOLEX snda for the Treatment of Osteoarthritis Pain in Adults First Lower Dose NSAID Using SoluMatrix Fine Particle Technology to be Reviewed
More informationThink Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks
NEWS AND PERSPECTIVES Think Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks Jyh-Ming Liou, 1,2 Ming-Shiang Wu, 1 * Jaw-Town Lin 1,3 Nonsteroidal
More informationEtodolac versus meloxicam
Etodolac versus meloxicam The Borg System is 100 % Etodolac versus meloxicam Etodolac versus meloxicam -- 722 75051 1991 Wainwright Not Specific Enough. The store also now says majority of Irish willing
More informationM Frezza, N Gorji, M Melato. The chronic use of non-steroidal antiinflammatory
J Clin Pathol 2001;54:521 525 521 Unit of Gastroenterology, General Hospital, I-34149 Trieste, Italy M Frezza Department of Pathological Anatomy, General Hospital and University of Trieste N Gorji M Melato
More informationPEPTIC ULCER IN RHEUMATOID ARTHRITIS- INTRINSIC OR RELATED TO DRUG THERAPY?
British Journal of Rheumatology 1986;25:342-344 PEPTIC ULCER IN RHEUMATOID ARTHRITIS- INTRIIC OR RELATED TO DRUG THERAPY? BY D. E. MALONE, P. A. McCORMICK, L. DALY, B. JONES, A. LONG, B. BRESNIHAN, J.
More informationTIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain
TIVORBEX Now Available in U.S. Pharmacies for the Treatment of Acute Pain Second Low-Dose SoluMatrix NSAID from Iroko Now Available by Prescription PHILADELPHIA, June 29, 2015 Iroko Pharmaceuticals, LLC,
More informationSunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Rheumatology 2003;42(Suppl. 3):iii32 iii39 doi:10.1093/rheumatology/keg496, available online at www.rheumatology.oupjournals.org Measuring dyspepsia-related health in randomized trials: the Severity of
More informationOsteoarthritis Research Society /98/ $12.00/0
Osteoarthritis and Cartilage (1998) 6, (Supplement A), 31 36 9 1998 Osteoarthritis Research Society 1063-4584/98/030031 + 06 $12.00/0 OSTEOARTHRITIS and CARTILAGE Efficacy and tolerability of oral chondroitin
More information... REPORTS... The Use and Effect of Analgesics in Patients Who Regularly Drink Alcohol. Richard C. Dart, MD, PhD
... REPORTS... The Use and Effect of Analgesics in Patients Who Regularly Drink Alcohol Richard C. Dart, MD, PhD Abstract Analgesic consumption poses special risks for regular users of alcohol. Among the
More informationOriginal Article. Rattanasupar A Attasaranya S Ovartlarnporn B ABSTRACT
74 THAI J GASTROENTEROL 2010 Esophagogastroduodenoscopy (EGD) plus Transabdominal Ultrasound (TUS) for Diagnosed Dyspepsia in Elderly Patients Original Article Esophagogastroduodenoscopy (EGD) plus Transabdominal
More informationDrug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs)
Drug Class Review Nonsteroidal Antiinflammatory Drugs (NSAIDs) Final Update 4 Report November 2010 The purpose of the is to summarize key information contained in the Drug Effectiveness Review Project
More informationIbuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception
Aliment Pharmacol Ther 2000; 14: 187±191. Ibuprofen versus other non-steroidal anti-in ammatory drugs: use in general practice and patient perception C. J. HAWKEY 1,D.J.E.CULLEN 1,9,G.PEARSON 1,S.HOLMES
More informationNOTOPAIN CAPLETS. Diclofenac Sodium + Paracetamol. Composition. Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg.
NOTOPAIN CAPLETS Diclofenac Sodium + Paracetamol Composition Each tablet contains: Diclofenac Sodium BP 50mg Paracetamol BP 500mg Pharmacology Phamacodynamics Diclofenac relieves pain and inflammation
More information